Market Place
Sourcing Support
Rakovina Therapeutics To Unveil New Data At AACR Annual Meeting
23 Mar 2026 //
GLOBENEWSWIRE
Rakovina Therapeutics Extends Non-Brokered Private Placement
12 Mar 2026 //
GLOBENEWSWIRE
Rakovina Therapeutics Reveals $1.5M Financing, Leadership
27 Jan 2026 //
GLOBENEWSWIRE
Rakovina, Variational AI Expand ATR Inhibitor Collaboration
08 Jan 2026 //
GLOBENEWSWIRE
Rakovina Therapeutics To Host Webinar With Variational AI
10 Dec 2025 //
GLOBENEWSWIRE
Rakovina Therapeutics: Q3 2025 Results and Corporate Update
01 Dec 2025 //
GLOBENEWSWIRE
Rakovina Therapeutics Extends Debentures With Debentureholder
28 Nov 2025 //
GLOBENEWSWIRE
Rakovina Presents Preclinical Data On CNS ATR mTOR Inhibitors
24 Nov 2025 //
GLOBENEWSWIRE
Rakovina Therapeutics Presents 2nd Abstract at SNO 2025
24 Nov 2025 //
GLOBENEWSWIRE
Rakovina Showcases CNS-Penetrant ATR & PARP1 Inhibitors
10 Nov 2025 //
GLOBENEWSWIRE
Rakovina Showcases AI-Based ATR Inhibitors with CNS Penetrance
27 Oct 2025 //
GLOBENEWSWIRE
Rakovina Therapeutics Showcase ATR Inhibitor With CNS Penetration
16 Oct 2025 //
GLOBENEWSWIRE
Rakovina CSO to Present at 13th Tuscany Cancer Research
26 Aug 2025 //
GLOBENEWSWIRE
Rakovina Therapeutics boosts innovation with strong AI-focused
10 Jul 2025 //
GLOBENEWSWIRE
Rakovina Therapeutics Announces 2024 Financial Results & Update
30 Apr 2025 //
GLOBENEWSWIRE
Rakovina`s AI-Driven ATR Inhibitors in Preclinical Testing
12 Mar 2025 //
GLOBENEWSWIRE
Rakovina Therapeutics Announces Listing on Stock Exchange
30 Jan 2025 //
GLOBENEWSWIRE
Rakovina Marks Milestone In Cancer Drug Collaboration With AI
13 Jan 2025 //
GLOBENEWSWIRE
Rakovina Advances AI-Derived Drugs To Preclinical Validation
06 Jan 2025 //
GLOBENEWSWIRE
Rakovina to Join 43rd Annual J.P. Morgan Conference Week
03 Jan 2025 //
GLOBENEWSWIRE
Rakovina Closes Oversubscribed $3M Private Placement
13 Dec 2024 //
GLOBENEWSWIRE
Rakovina Therapeutics to Present at Tumour Models London Summit
03 Dec 2024 //
GLOBENEWSWIRE
Rakovina Therapeutics Raises Private Placement Offering To $3M
02 Dec 2024 //
GLOBENEWSWIRE
Rakovina Announces Q3 2024 Financial Results, Corporate Update
29 Nov 2024 //
GLOBENEWSWIRE
Rakovina Therapeutics Increases Private Placement To $2.5M
28 Nov 2024 //
GLOBENEWSWIRE
Rakovina Therapeutics Announces Private Placement Offering
27 Nov 2024 //
GLOBENEWSWIRE
Rakovina Presents AI-Driven Drug Discovery Research at SNO Meeting
25 Nov 2024 //
GLOBENEWSWIRE
Rakovina Therapeutics To Present At Society For Neuro-Oncology
20 Nov 2024 //
GLOBENEWSWIRE
Rakovina Therapeutics to Highlight PARP1/2 Inhibitors at EORTC
25 Oct 2024 //
GLOBENEWSWIRE
Rakovina Announces Initial Drug Candidates from AI Platform
23 Oct 2024 //
GLOBENEWSWIRE
Rakovina Therapeutics and Variational AI Announce Drug Discovery Pact
17 Sep 2024 //
GLOBENEWSWIRE
Rakovina Partners For AI-Driven Cancer Target Selection
17 Sep 2024 //
FIERCE BIOTECH
Rakovina Welcomes Prof. Artem Cherkasov to Company™s Scientific Advisory Board
27 Nov 2023 //
GLOBENEWSWIRE
Rakovina Announces Appointment of New Scientific Advisory Board Member
20 Nov 2023 //
GLOBENEWSWIRE
